首个人体Ⅰ期剂量递增与剂量扩展研究:靶向滋养层细胞表面抗原2的抗体药物偶联物Datopotamab deruxtecan治疗非小细胞肺癌的TROPION-PanTumor01研究
该首个人体Ⅰ期剂量递增与扩展研究评估了靶向滋养层细胞表面抗原2(TROP2)的抗体药物偶联物Datopotamab deruxtecan(Dato-DXd)在晚期非小细胞肺癌(NSCLC)中的安全性、耐受性和抗肿瘤活性。210例患者接受Dato-DXd,其中180例在4-8 mg/kg剂量扩展队列;最大耐受剂量为8 mg/kg每3周一次,推荐进一步开发剂量为6 mg/kg每3周一次。6 mg/kg组(n=50)客观缓解率为26%(95%CI 14.6-40.3),中位缓解持续时间10.5个月,中位无进展生存期6.9个月(95%CI 2.7-8.8),中位总生存期11.4个月(95%CI 7.1-20.6)。
要点
- 最大耐受剂量为8 mg/kg每3周一次,推荐进一步开发剂量为6 mg/kg每3周一次。
- 6 mg/kg组(n=50)客观缓解率26%(95%CI 14.6-40.3),中位缓解持续时间10.5个月。
- 6 mg/kg组中位无进展生存期6.9个月(95%CI 2.7-8.8),中位总生存期11.4个月(95%CI 7.1-20.6)。
核心结论
- Dato-DXd在经重度治疗的晚期NSCLC患者中显示出有前景的抗肿瘤活性和可控的安全性。
- 作为晚期NSCLC一线联合治疗以及二线及以后单药治疗的进一步研究正在进行中。
研究设计与样本
- 首个人体、剂量递增和剂量扩展研究,评估Dato-DXd在实体瘤(包括晚期NSCLC)中的安全性、耐受性和抗肿瘤活性。
- 局部晚期/转移性NSCLC成人患者在递增阶段接受0.27-10 mg/kg Dato-DXd每3周一次,在扩展阶段接受4、6或8 mg/kg Dato-DXd每3周一次。
- 主要终点为安全性和耐受性;次要终点包括客观缓解率、生存和药代动力学。
- 共210例患者接受Dato-DXd,其中180例在4-8 mg/kg剂量扩展队列;该人群中位既往治疗线数为三线。
主要发现
- 最大耐受剂量为8 mg/kg每3周一次;推荐进一步开发剂量为6 mg/kg每3周一次。
- 6 mg/kg组(n=50)中位研究持续时间(包括随访)和中位暴露时间分别为13.3个月和3.5个月。
- 最常见任何级别治疗中出现的不良事件(TEAE)为恶心(64%)、口腔炎(60%)和脱发(42%)。
- ≥3级TEAE和治疗相关AE分别发生于54%和26%的患者。
- 经判定为药物相关的间质性肺病(2级2例、4级1例)发生于6 mg/kg组50例患者中的3例(6%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This first-in-human, dose-escalation and dose-expansion study evaluated the safety, tolerability, and antitumor activity of datopotamab deruxtecan (Dato-DXd), a novel trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate in solid tumors, including advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Adults with locally advanced/metastatic NSCLC received 0.27-10 mg/kg Dato-DXd once every 3 weeks during escalation or 4, 6, or 8 mg/kg Dato-DXd once every 3 weeks during expansion. Primary end points were safety and tolerability. Secondary end points included objective response rate (ORR), survival, and pharmacokinetics. RESULTS: Two hundred ten patients received Dato-DXd, including 180 in the 4-8 mg/kg dose-expansion cohorts. This population had a median of three prior lines of therapy. The maximum tolerated dose was 8 mg/kg once every 3 weeks; the recommended dose for further development was 6 mg/kg once every 3 weeks. In patients receiving 6 mg/kg (n = 50), median duration on study, including follow-up, and median exposure were 13.3 and 3.5 months, respectively. The most frequent any-grade treatment-emergent adverse events (TEAEs) were nausea (64%), stomatitis (60%), and alopecia (42%). Grade ≥3 TEAEs and treatment-related AEs occurred in 54% and 26% of patients, respectively. Interstitial lung disease adjudicated as drug-related (two grade 2 and one grade 4) occurred in three of 50 patients (6%). The ORR was 26% (95% CI, 14.6 to 40.3), and median duration of response was 10.5 months; median progression-free survival and overall survival were 6.9 months (95% CI, 2.7 to 8.8 months) and 11.4 months (95% CI, 7.1 to 20.6 months), respectively. Responses occurred regardless of TROP2 expression. CONCLUSION: Promising antitumor activity and a manageable safety profile were seen with Dato-DXd in heavily pretreated patients with advanced NSCLC. Further investigation as first-line combination therapy in advanced NSCLC and as monotherapy in the second-line setting and beyond is ongoing.
引用
- Shimizu T, Sands J, Yoh K, et al. First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01. J Clin Oncol. 2023. PMID: 37327461. doi:10.1200/JCO.23.00059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。